News
Public · Published
Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer — Barrons.com
Tempus AI reported third-quarter adjusted earnings of 7 cents a share, versus analysts' expected loss of 8 cents, while revenue rose 23% year over year to $411.5 million. Oncology testing volumes grew 32%, and tests for signs of cancer returning after treatment rose 300% to about 12,000. The company is moving toward completing its $1.5 billion purchase of Personalis.
Published:
Updated:
What happened
Tempus AI reported third-quarter adjusted earnings of 7 cents a share, versus analysts’ expected loss of 8 cents, while revenue rose 23% year over year to $411.5 million. Oncology testing volumes grew 32%, and tests for signs of cancer returning after treatment rose 300% to about 12,000. The company is moving toward completing its $1.5 billion purchase of Personalis.
Confirmed
Global impact / market context
Faster cancer-testing demand directly supports Tempus’s revenue growth, while improved earnings show the company exceeded analysts’ expectations for the quarter. Completing Personalis could expand its cancer-detection capabilities, but the purchase also requires substantial funding; the article gives no details on financing or expected financial benefits.
Analyst inference
Tempus’s results combine stronger testing volumes and revenue with progress toward a large acquisition, making execution important to the business outlook. The stock rose 3.9% in premarket trading after a 7.2% Friday decline, but remained about 26% below its October 2025 closing high.
Confirmed
What to watch
- Watch whether oncology testing volumes and revenue continue growing in later reports; sustained demand would support the operating growth shown this quarter. Analyst inference
- Watch for the completion of the proposed $1.5 billion Personalis acquisition and any disclosed funding terms, which could clarify its cash cost to Tempus. Proposed
- Watch whether Tempus reports continued growth in minimal residual disease testing, which detects possible cancer return after treatment and rose to about 12,000 tests. Analyst inference
Evidence
- Original source link unavailable